Physician profile
David E Devoid
NPI 1326012758
$6,494.18
in general payments reported to CMS, 2019-2025
41 companies · $1,205 in 2025
The $1,205 reported for 2025 was more than what 84% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $379 · 2021: $1,386 · 2022: $1,102 · 2023: $1,138 · 2024: $935 · 2025: $1,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,179 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,179.27 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,751.49 | 2019-2025 | Creon, Linzess, Mavyret |
| Alcresta Therapeutics, INC. | $809.27 | 2022-2024 | Relizorb |
| Regeneron Healthcare Solutions, INC. | $450.53 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $429.37 | 2019-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $428.28 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $401.59 | 2020-2023 | |
| Janssen Biotech, INC. | $367.57 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $346.23 | 2020-2025 | Eohilia, Gattex |
| Gilead Sciences, INC. | $228.47 | 2021-2025 | |
| Intra-Sana Laboratories | $199.26 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Pfizer INC. | $120.10 | 2019-2021 | |
| Mirum Pharmaceuticals, INC. | $111.35 | 2022-2025 | Livmarli |
| Endogastric Solutions, INC | $90.18 | 2022-2023 | Esophyx |
| Madrigal Pharmaceuticals | $70.73 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $58.42 | 2024-2025 | Bylvay |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Albireo Pharma, INC. | $52.90 | 2022-2023 | Bylvay |
| Aimmune Therapeutics, INC. | $46.85 | 2025 | Zenpep |
| Amgen INC. | $45.73 | 2020-2022 | |
| Medtronic, INC. | $40.95 | 2022-2024 | Interstim |
| Celltrion USA INC. | $40.41 | 2025 | Vegzelma |
| Rhythm Pharmaceuticals, INC. | $38.74 | 2024-2025 | Imcivree |
| Organon LLC | $32.83 | 2023 | Renflexis, Hadlima |
| Fresenius Kabi USA, LLC | $27.16 | 2023 | Idacio |
| Ars Pharmaceuticals Operations, INC. | $26.28 | 2025 | Neffy |
| Acadia Pharmaceuticals INC | $24.42 | 2025 | Daybue |
| Vivus LLC | $23.74 | 2021 | |
| Novo Nordisk INC | $21.28 | 2025 | Wegovy |
| Soleno Therapeutics, INC. | $20.59 | 2025 | Vykat Xr |
| Kaleo, INC. | $19.55 | 2022 | |
| Genentech USA, INC. | $18.14 | 2024 | Xolair |
| Orphalan INC | $17.41 | 2025 | Cuvrior |
| Shire North American Group INC | $16.60 | 2019 | |
| Pharming Healthcare, INC. | $16.59 | 2022 | |
| Echosens North America, INC. | $16.28 | 2024 | Fibroscan |
| Biogen, INC. | $15.41 | 2022 | |
| Coloplast Corp | $14.40 | 2025 | |
| Sandoz INC. | $14.07 | 2023 | Hyrimoz |
| Merck Sharp & Dohme LLC | $13.00 | 2020 | |
| Horizon Therapeutics Plc | $11.47 | 2019 | |
| Cook Medical LLC | $11.28 | 2019 | |
| Romark Laboratories, Lc | $5.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Devoid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.